Neusoft Medical, Q3 2020, Sales Results

On October 30th, Neusoft Medical published its financial results for Q3 2020. These show that sales returned to growth during the quarter, although remain lower for the year. Total sales reached CNY ¥1.79bn, compared with CNY ¥1.69bn during Q3 2019, an increase of approximately +5.7% year-on-year. This took cumulative 2020 sales to CNY ¥4.27bn, compared with CNY ¥4.62bn during 2019, a decrease of approximately -7.6% year-on-year.

Company Biography

Neusoft Medical Systems Co., Ltd. (Neusoft Medical) is a leading global clinical diagnosis and treatment solution provider. Headquartered in China, with subsidiaries in the United States, Dubai, Peru, Russia, Brazil, Kenya, Germany, Korea, Thailand and a representative office in Vietnam. Neusoft Medical is constantly innovating its portfolio of medical imaging diagnosis and clinical solutions in CT, MRI, DSA, XR, PET/CT, RT, US and IVD. Neusoft Medical also is developing MDaaS (Medical Devices & Data as a Service), a strategic product line built using the Internet, big data, artificial intelligence, combined with other technologies improving medical institutions’ ability to diagnose and treat patients, achieving operational excellence. Innovation is always the driving force of Neusoft Medical. The global R&D centers are located in Houston, Seoul, Beijing, Shanghai, Shenyang, Guangzhou and Nanjing. Neusoft Medical is collaborating with global scientists and medical institutions dedicated to advancing the technology of medical imaging solutions. Together with 38,000 installations in more than 100 countries, Neusoft Medical provides advanced, high-quality medical imaging solutions to patients around the world. Neusoft Medical is dedicated to becoming an excellent value innovator of global healthcare services. Through innovation and excellent operations, Neusoft Medical Systems is advancing healthcare products across a wide range of medical solutions and services to enhance global healthcare to all.

Processing…
Success! You're on the list.